A Phase 4 interventional study of Research MRI without administration of intravenous secretin and Research MRI with administration of intravenous secretin in Pancreatitis and Diabetes Mellitus, sponsored by Children's Hospital Medical Center, Cincinnati. Enrolling by invitation at 1 site in United States. Open to participants aged 5 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Pancreatitis with a site in United States — 44 open to participants now, 49 under way, 2 of them phase 3. Pancreatitis · United States.
Among the 139 studies in Pancreatitis with a site in United States, this one is the 18th largest by planned enrollment of the 97 interventional ones that give a count, is one of 10 that started in 2023, is one of 11 in phase 4, reaches primary completion later than 11 of the 48 other live ones, and was the 110th registered.
558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.
Browse Pancreatitis studies →44 of the 139 studies in Pancreatitis with a site in United States are open now. Recruiting first, the newest first:
Christopher C. Thompson, MD, MSc · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+
Anna Evans Phillips · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–80
University of Southern California · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.
This study: 5 Years to 21 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 30 · Phase 3 9 · Phase 4 11
First in 1997; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 195 is above the median of 100 across 349 interventional studies indexed under Pancreatitis.
Median enrollment 60 across the 97 interventional studies, 433 across the 41 observational. Of the 76 that completed or were terminated, 37 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 139 have an industry lead sponsor. The 10 most frequent:
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
Children's Hospital Medical Center, Cincinnati has 2 studies filed under Pancreatitis — fewer than ten, so there is no comparison to draw.
18 of the studies in Pancreatitis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05252754Phase 3Johns Hopkins UniversityRectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis | 2026-12 |
| NCT06691893Phase 3Massachusetts General HospitalEvaluating the Efficacy of RELiZORB in Managing Exocrine Pancreatic Insufficiency in Tube-fed Pancreatitis Patients | 2027-04-15 |
| NCT07583342Northwell HealthEvaluating RELiZORB Use for the Treatment of Feeding Intolerance in Adults With Moderate to Severe Acute Pancreatitis | 2026-12 |
| NCT05659147Children's Hospital Medical Center, CincinnatiImaging Biomarkers of Pancreatic Function and Disease | 2026-12 |
| NCT06080789Panafina, Inc.A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 139 studies in Pancreatitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study seeks to understand the performance of MRI to characterize pancreatitis and predict chronic complications (endocrine and exocrine) of pancreatitis. Through multiple aims, the investigators will benchmark MRI against relevant reference standards (e.g. endoscopic pancreatic function tests, laboratory data). The investigators will also characterize repeatability of the imaging findings and will work to develop methods to simplify and automate analysis of the MRI images.
Research interventions depend on the Aim(s) participants enroll in but include: endoscopic pancreatic function testing (added on to clinically indicated upper GI endoscopy), blood tests, stool tests, gene sequencing, and survey completion. All participants will undergo research MRI examinations, a subset of which will include administration of intravenous secretin.
Pancreatitis can be acute [AP], acute recurrent [ARP] (defined as two discrete attacks with interval resolution), or chronic [CP]. Adult studies show that up to 40% of patients develop abnormal glucose metabolism after a single attack of AP, with a 2.5x increased risk of diabetes. CP is defined, in part, by the presence of established endocrine (diabetes) or exocrine pancreatic insufficiency [EPI]. Currently, it is not possible to non-invasively diagnose or predict development of pancreatitis-related endocrine or exocrine insufficiency.
The investigator's data has shown that CFTR gene variants play a significant role in progression to diabetes post first attack AP. Existing literature suggests that imaging findings such as decreased pancreas volume are associated with diabetes, but this has not been systematically studied in children.
EPI, defined as insufficient secretion of digestive enzymes and fluid by the pancreas, can have significant effects in childhood including malnutrition, osteoporosis, and growth failure. If diagnosed early, EPI can be treated with pancreatic enzyme replacement, improving nutrition and stabilizing growth. Unfortunately, diagnosing EPI early and accurately is a challenge in children and it is currently not possible to predict progression to CP or development of EPI.
Magnetic resonance imaging (MRI) is a powerful, non-invasive technique, capable of characterizing pancreatic disease. Quantitative non-contrast MRI techniques are attractive as potential markers of pancreatic disease but they have not been validated for diagnosis or prediction of diabetes or EPI in children and they have not been explored for staging of pediatric pancreatitis.
The overall goals of this study are to:
Aim 1-
Patient Group:
Inclusion Criteria:
Exclusion Criteria:
Control Group:
Inclusion Criteria:
Exclusion Criteria:
Aim 2-
Acute Pancreatitis Group:
Inclusion Criteria:
Exclusion Criteria:
Acute Recurrent Pancreatitis Group:
Inclusion Criteria:
Exclusion Criteria:
Pancreatitis-Related Diabetes Group:
Inclusion Criteria:
Exclusion Criteria:
Aim 3-
Control Group:
Inclusion Criteria:
Exclusion Criteria:
Acute Pancreatitis Group:
Inclusion Criteria:
Exclusion Criteria:
Acute Recurrent Pancreatitis Group:
Inclusion Criteria:
Exclusion Criteria:
Chronic Pancreatitis Group:
Inclusion Criteria:
Exclusion Criteria:
Aim 4-
Inclusion Criteria:
Exclusion Criteria:
Aim 5-
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
We will prospectively enroll 85 participants; 40 with known or suspected EPI and 45 controls (no known organic gastrointestinal pathology and no history of pancreatic disease) in this aim. Participants will be undergoing clinically-indicated endoscopy and will have endoscopic pancreatic function tests (ePFTs) collected for research during the clinically-indicated endoscopy examination. A research blood draw and a research stool collection will also be collected from all participants. Participants will undergo a research MRI examination with administration of intravenous secretin within 2 weeks of their clinical endoscopy but no sooner than 2 hours before or after endoscopy.
Diagnostic Test: Research MRI with administration of intravenous secretin · Diagnostic Test: Blood Tests · Diagnostic Test: Stool Tests · Other: Survey Completion · Diagnostic Test: Endoscopic pancreatic function tests (ePFTs) · Drug: Secretin
We will prospectively enroll 30 participants; 10 with a single episode of acute pancreatitis, 10 with acute recurrent pancreatitis, and 10 with pancreatitis-related diabetes in this aim. Participants will undergo a research MRI examination. Participants will also undergo a research blood draw for laboratory analysis and to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.
Diagnostic Test: Research MRI without administration of intravenous secretin · Genetic: Genetic Sequencing · Diagnostic Test: Blood Tests · Other: Survey Completion
We will prospectively enroll 60 participants; 15 healthy controls, 15 participants with a single episode of acute pancreatitis, 15 participants with acute recurrent pancreatitis, and 15 participants with chronic pancreatitis. A research blood draw and a research stool collection will be collected from all participants. Participants will undergo a research MRI examination with administration of intravenous secretin.
Diagnostic Test: Research MRI with administration of intravenous secretin · Diagnostic Test: Blood Tests · Diagnostic Test: Stool Tests · Other: Survey Completion · Drug: Secretin
We will prospectively enroll up to 20 participants enrolled in Aims 1 or 3 (up to 5 controls and 15 patients with pancreatic disease) to undergo repeat research MRI imaging between 24 hours and 14 days after their first research MRI. Participants will undergo a research MRI examination with administration of intravenous secretin, identical to the research MRI performed under Aims 1 or 3. MRI images will be quantitatively analyzed and agreement between the two MRI examinations (1st and repeat MRI) will be assessed.
Diagnostic Test: Research MRI with administration of intravenous secretin · Drug: Secretin
We will use images prospectively collected under Aims 1-3, as well as existing images that had been obtained for clinical care of children with pancreatitis at CCHMC to develop and optimize image processing pipelines for MRI images. Performance of these pipelines will be benchmarked against manual segmentation performed by multiple observers.
Participants will undergo a research MRI examination. MRI images will be quantitatively analyzed and will be compared to / used to predict diabetes.
Participants will undergo a research MRI examination with intravenous administration of secretin. MRI images will be quantitatively analyzed and will be compared to / used to predict exocrine and endocrine pancreatic insufficiency based on the reference standards of ePFTs or fecal elastase and blood hemoglobin A1c (HbA1c) and fasting glucose, respectively.
Blood will be drawn to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.
Research blood draw (for markers of pancreatic endocrine insufficiency)
Research stool collection (for fecal elastase as a marker of exocrine insufficiency)
Participants will be contacted to complete a survey and their charts will be reviewed annually after research MRI to identify any evidence of subsequent development of pancreatic endocrine insufficiency or progression of pancreatitis. Survey and chart review will occur within +/- 14 days of the anniversary date.
At least two duodenal fluid aspirates will be collected over 15 minutes following secretin administration. Aspirates will be immediately pH tested and will be submitted for analysis of bicarbonate, enzyme (trypsin, amylase, lipase, chymotrypsin) activity, and total protein.
Participants enrolled in Aim 1, Aim 3, and Aim 4 will receive intravenous secretin at a dose of 0.2 mcg/kg (maximum 16 mcg). Participants in Aim 1 will receive two doses (1 during endoscopy and 1 during MRI). Participants in Aim 3 will receive one dose during MRI. Participants in Aim 4 will receive two doses (1 during each MRI). Secretin for intravenous use is FDA-approved for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction. Safety and effectiveness of secretin in pediatrics have not been established. However, secretin is routinely used in children at CCHMC at the same dose at which it will be administered for this study.
Pancreas volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
2 x 2 table analyses of pancreas volume (categorized as normal vs. abnormal) vs. exocrine function (categorized as normal vs. abnormal)
Time frame: 5 years
Pancreas volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
2 x 2 table analyses of pancreas volume (categorized as normal vs. abnormal) vs. endocrine function (categorized as normal vs. abnormal)
Time frame: 5 years
Pancreas T1 signal as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
2 x 2 table analyses of pancreas T1 signal (categorized as normal vs. abnormal) vs. exocrine function (categorized as normal vs. abnormal)
Time frame: 5 years
Pancreas T1 signal as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
2 x 2 table analyses of pancreas T1 signal intensity (categorized as normal vs. abnormal) vs. endocrine function (categorized as normal vs. abnormal)
Time frame: 5 years
Pancreas secreted fluid volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
2 x 2 table analyses of pancreas secreted fluid volume (categorized as normal vs. abnormal) vs. exocrine function (categorized as normal vs. abnormal)
Time frame: 5 years
Pancreas secreted fluid volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).
2 x 2 table analyses of pancreas secreted fluid volume (categorized as normal vs. abnormal) vs. endocrine function (categorized as normal vs. abnormal)
Time frame: 5 years
Frequency of genetic mutations in patients progressing to diabetes vs. those not
Frequency of genetic mutations in each study group will be compared using 2x2 tables to identify mutations associated with development of diabetes
Time frame: 5 years
PDFs hosted by the registry, ClinicalTrials.gov.
Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secretin
Children's Hospital Medical Center, Cincinnati →